epirubicin has been researched along with dexrazoxane in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aigner, B; Arzberger, EJ; Bauernhofer, T; Niederkorn, A; Petru, E; Richtig, E | 1 |
| Geng, C; Li, X; Qi, X; Sun, F | 1 |
| Ahmad, SF; Al-Khedhairy, AA; Attia, SM; Bakheet, SA; Harisa, GI; Saquib, Q | 1 |
| Geng, C; Shi, J; Sun, F | 1 |
2 review(s) available for epirubicin and dexrazoxane
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexrazoxane; Dimethyl Sulfoxide; Drug Eruptions; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Free Radical Scavengers; Humans; Middle Aged; Time Factors; Topoisomerase II Inhibitors | 2014 |
2 trial(s) available for epirubicin and dexrazoxane
| Article | Year |
|---|---|
Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotonic Agents; Cardiotoxicity; Cyclophosphamide; Dexrazoxane; Diabetes Mellitus, Type 2; Drug Monitoring; Epirubicin; Female; Heart Function Tests; Humans; Middle Aged; Treatment Outcome | 2015 |
Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes.
Topics: Antineoplastic Agents; Autonomic Nervous System; Breast Neoplasms; Dexrazoxane; Diabetes Mellitus, Type 2; Epirubicin; Female; Heart; Humans; Middle Aged; Prospective Studies | 2016 |
4 other study(ies) available for epirubicin and dexrazoxane
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Carcinogens; Cardiotonic Agents; Comet Assay; Dexrazoxane; DNA Breaks; Epirubicin; Male; Mice; Micronuclei, Chromosome-Defective; Micronucleus Tests; Mutagenicity Tests; Reactive Oxygen Species | 2016 |